Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice

Virology

Volumn 432, Issue 1, 2012, Pages 39-44

  Easterbrook, Judith D ^a   Schwartzman, Louis M ^a   Gao, Jin ^b   Kash, John C ^a   Morens, David M ^a   Couzens, Laura ^b   Wan, Hongquan ^b   Eichelberger, Maryna C ^b   Taubenberger, Jeffery K ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Cross protection; Vaccine; Virus like particle (VLP)

Indexed keywords

INFLUENZA VACCINE; MATRIX PROTEIN; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LETHALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SURVIVAL RATE; VIRUS LIKE AGENT;

ANIMALS; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, VIROSOME;

MUS;

EID: 84864013012     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.06.003     Document Type: Article

References (38)

1. Air, G.M., 2011. Influenza neuraminidase. Influenza Other Respir. Viruses, November 16, Epub ahead of print.
2. Aymard M., Ferraris O., Gerentes L., Jolly J., Kessler N. Neuraminidase assays. Dev. Biol. (Basel) 2003, 115:75-83.
3. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M.D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., Nicoll A., Touch S., Yuen K.Y. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 2005, 353(13):1374-1385.
4. Bessa J., Schmitz N., Hinton H.J., Schwarz K., Jegerlehner A., Bachmann M.F. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 2008, 38(1):114-126.
5. Blok J., Air G.M. Variation in the membrane-insertion and "stalk" sequences in eight subtypes of influenza type A virus neuraminidase. Biochemistry 1982, 21(17):4001-4007.
6. Brett I.C., Johansson B.E. Variation in the divalent cation requirements of influenza A virus N1 neuraminidases. J. Biochem. 2006, 139(3):439-447.
7. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., Ross T.M. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3(1):e1501.
8. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., Massare M., Pushko P., Mytle N., Rowe T., Smith G., Ross T.M. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
9. Cate T.R., Rayford Y., Nino D., Winokur P., Brady R., Belshe R., Chen W., Atmar R.L., Couch R.B. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28(9):2076-2079.
10. Chen Z., Kim L., Subbarao K., Jin H. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 2012, 30(15):2516-2522.
11. Easterbrook J.D., Kash J.C., Sheng Z.M., Qi L., Gao J., Kilbourne E.D., Eichelberger M.C., Taubenberger J.K. Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection. Influenza Other Respir. Viruses 2010, 5(3):198-205.
12. Horimoto T., Kawaoka Y. Designing vaccines for pandemic influenza. Curr. Top. Microbiol. Immunol. 2009, 333:165-176.
13. Ichinohe T., Tamura S., Kawaguchi A., Ninomiya A., Imai M., Itamura S., Odagiri T., Tashiro M., Takahashi H., Sawa H., Mitchell W.M., Strayer D.R., Carter W.A., Chiba J., Kurata T., Sata T., Hasegawa H. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 2007, 196(9):1313-1320.
14. Johansson B.E., Bucher D.J., Kilbourne E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 1989, 63(3):1239-1246.
15. Johansson B.E., Moran T.M., Bona C.A., Kilbourne E.D. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice. J. Immunol. 1987, 139(6):2015-2019.
16. Kang S.M., Pushko P., Bright R.A., Smith G., Compans R.W. Influenza virus-like particles as pandemic vaccines. Curr. Top. Microbiol. Immunol. 2009, 333:269-289.
17. Kendal A.P., Noble G.R., Dowdle W.R. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J. Infect. Dis. 1977, 136(Suppl.):S415-S424.
18. Khurana S., Wu J., Verma N., Verma S., Raghunandan R., Manischewitz J., King L.R., Kpamegan E., Pincus S., Smith G., Glenn G., Golding H. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies in humans that preferentially bind to oligomeric form of influenza hemagglutinin. J. Virol. 2011, 85(21):10945-10954.
19. Kilbourne E.D., Johansson B.E., Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl. Acad. Sci. USA 1990, 87(2):786-790.
20. Kilbourne E.D., Pokorny B.A., Johansson B., Brett I., Milev Y., Matthews J.T. Protection of mice with recombinant influenza virus neuraminidase. J. Infect. Dis. 2004, 189(3):459-461.
21. Lai J.C., Chan W.W., Kien F., Nicholls J.M., Peiris J.S., Garcia J.M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J. Gen. Virol. 2010, 91(Part 9):2322-2330.
22. Lin X., Zhou J., Zhang Y., Wu J., Zhang F., Li Z., Bi S., Shu Y., Wang Y. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. Biochem. Biophys. Res. Commun. 2009, 390(4):1305-1308.
23. McBurney S.P., Young K.R., Ross T.M. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007, 358(2):334-346.
24. Memoli M.J., Tumpey T.M., Jagger B.W., Dugan V.G., Sheng Z.M., Qi L., Kash J.C., Taubenberger J.K. An early 'classical' swine H1N1 influenza virus shows similar pathogenicity to the 1918 pandemic virus in ferrets and mice. Virology 2009, 393(2):338-345.
25. Monto A.S., Kendal A.P. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973, 1(7804):623-625.
26. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 1972, 286(25):1329-1332.
27. Nguyen T.H., Farrar J., Horby P. Person-to-person transmission of influenza A (H5N1). Lancet 2008, 371(9622):1392-1394.
28. Peiris J.S., de Jong M.D., Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 2007, 20(2):243-267.
29. Perrone L.A., Ahmad A., Veguilla V., Lu X., Smith G., Katz J.M., Pushko P., Tumpey T.M. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 2009, 83(11):5726-5734.
30. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 2007, 81(7):3514-3524.
31. Saito T., Taylor G., Webster R.G. Steps in maturation of influenza A virus neuraminidase. J. Virol. 1995, 69(8):5011-5017.
32. Sandbulte M.R., Gao J., Straight T.M., Eichelberger M.C. A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir. Viruses 2009, 3(5):233-240.
33. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 2007, 4(2):e59.
34. Sandbulte M.R., Westgeest K.B., Gao J., Xu X., Klimov A.I., Russell C.A., Burke D.F., Smith D.J., Fouchier R.A., Eichelberger M.C. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. USA 2011, 108(51):20748-20753.
35. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., Hogan R.J., Wu Z., Benton K.A., Tumpey T.M., Epstein S.L. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 2007, 13(3):426-435.
36. Tumpey T.M., Basler C.F., Aguilar P.V., Zeng H., Solorzano A., Swayne D.E., Cox N.J., Katz J.M., Taubenberger J.K., Palese P., Garcia-Sastre A. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005, 310(5745):77-80.
37. Wang T.T., Parides M.K., Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science 2012, 335(6075):1463.
38. Wu J., Zhang F., Wang M., Xu C., Song J., Zhou J., Lin X., Zhang Y., Wu X., Tan W., Lu J., Zhao H., Gao J., Zhao P., Wang Y. Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza A viruses. PLoS One 2010, 5(12):e15825.